{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:33:39Z","timestamp":1791686019375,"version":"4.3.4"},"reference-count":109,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008149","name":"Royal College of Pathologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008149","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic antifungal therapy is critical for reducing the mortality from many invasive and chronic fungal infections. Triazole antifungals are the most frequently prescribed antifungals but require attention to dosing and drug interactions. Nearly 600 severe drug\u2013drug interactions and over 1100 moderate interactions requiring dose modifications are described or anticipated with systemic antifungal agents (see https:\/\/www.aspergillus.org.uk\/antifungal-drug-interactions\/). In this article, we address the common and less common, but serious, drug interactions observed in clinical practice with triazole antifungals, including a group of drugs that cannot be prescribed with all or most triazole antifungals (ivabradine, ranolazine, eplerenone, fentanyl, apomorphine, quetiapine, bedaquiline, rifampicin, rifabutin, sirolimus, phenytoin and carbamazepine). We highlight interactions with drugs used in children and new agents introduced for the treatment of haematological malignancies or graft versus host disease (midostaurin, ibrutinib, ruxolitinib and venetoclax). We also summarize the multiple interactions between oral and inhaled corticosteroids and triazole antifungals, and the strategies needed to optimize the therapeutic benefits of triazole antifungal therapy while minimizing potential harm to patients.<\/jats:p>","DOI":"10.1093\/jac\/dkae103","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T20:16:11Z","timestamp":1712175371000},"page":"1203-1217","source":"Crossref","is-referenced-by-count":43,"title":["Triazole antifungal drug interactions\u2014practical considerations for excellent prescribing"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-4339","authenticated-orcid":false,"given":"Russell","family":"Lewis","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Padua , Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9976-4243","authenticated-orcid":false,"given":"Saarah","family":"Niazi-Ali","sequence":"additional","affiliation":[{"name":"Antifungal Database Consultancy Pharmacist, Fungal Infection Trust , PO Box 482, Macclesfield, Cheshire SK10 9AR ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McIvor","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souha S","family":"Kanj","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine and Center for Infectious Diseases Research, American University of Beirut Medical Center , Beirut ,","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, Department of Haematology, University Hospitals Leuven, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Infectious Diseases Clinic, University of Genoa and Ospedale Policlinico San Martino IRCCS , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Levine","sequence":"additional","affiliation":[{"name":"Lung Transplant Program, Division of Pulmonary Critical Care and Allergy, Department of Medicine, Stanford University , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-393X","authenticated-orcid":false,"given":"Andreas H","family":"Groll","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology\/Oncology, Children\u2019s University Hospital , Albert-Schweitzer-Campus 1, Building A1, M\u00fcnster, 48149 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Denning","sequence":"additional","affiliation":[{"name":"Manchester Fungal Infection Group, The University of Manchester and Manchester Academic Health Science Centre , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2025041611020814900_dkae103-B1","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00054-16","article-title":"Drug-drug interaction associated with mold-active triazoles among hospitalized patients","volume":"60","author":"Andes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025041611020814900_dkae103-B2","article-title":"Drug-drug interaction database for safe prescribing of systemic antifungal agents","volume":"8","author":"Niazi-Ali","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"2025041611020814900_dkae103-B3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2025041611020814900_dkae103-B4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025041611020814900_dkae103-B5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025041611020814900_dkae103-B6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025041611020814900_dkae103-B7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1586\/ecp.11.30","article-title":"Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs","volume":"4","author":"Imai","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B8","first-page":"2437","volume-title":"Feigin and Cherry\u2019s Textbook of Pediatric Infectious Diseases","author":"Groll","year":"2019","edition":"8th edn"},{"key":"2025041611020814900_dkae103-B9","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1097\/INF.0000000000003659","article-title":"New developments in pediatric antifungal pharmacology","volume":"41","author":"Groll","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"2025041611020814900_dkae103-B10","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/jac\/dkad107","article-title":"Drug\u2013drug interaction: decreased posaconazole trough concentrations during concomitant flucloxacillin treatment","volume":"78","author":"Wortman","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025041611020814900_dkae103-B11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40272-022-00547-6","article-title":"Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients","volume":"25","author":"K\u00f6rholz","year":"2023","journal-title":"Paediatr Drugs"},{"key":"2025041611020814900_dkae103-B12","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1473-3099(17)30303-1","article-title":"Fungal infections in HIV\/AIDS","volume":"17","author":"Limper","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025041611020814900_dkae103-B13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1345\/aph.1L607","article-title":"Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis","volume":"43","author":"Carbonara","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2025041611020814900_dkae103-B14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.2007.03085.x","article-title":"Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers","volume":"65","author":"Damle","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270007309703","article-title":"Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects","volume":"48","author":"Liu","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B16","volume-title":"Vfend Prescribing Information","author":"Pfizer Inc","year":"2019"},{"key":"2025041611020814900_dkae103-B17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome p450 3a4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"key":"2025041611020814900_dkae103-B18","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.3390\/ijms23179866","article-title":"The mechanism-based inactivation of cyp3a4 by ritonavir: what mechanism","volume":"23","author":"Loos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025041611020814900_dkae103-B19","author":"Pfizer Inc"},{"key":"2025041611020814900_dkae103-B20","author":"NIH, COVID-19 Treatment Guidelines Panel"},{"key":"2025041611020814900_dkae103-B21","doi-asserted-by":"crossref","first-page":"20402","DOI":"10.1038\/s41598-019-56013-w","article-title":"Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis","volume":"9","author":"Yang","year":"2019","journal-title":"Sci Rep"},{"key":"2025041611020814900_dkae103-B22","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025041611020814900_dkae103-B23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/clinids\/14.1.165","article-title":"Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations","volume":"14","author":"Tucker","year":"1992","journal-title":"Clin Infect Dis"},{"key":"2025041611020814900_dkae103-B24","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/jac\/dkt229","article-title":"Steady-state pharmacokinetics and metabolism of voriconazole in patients","volume":"68","author":"Geist","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025041611020814900_dkae103-B25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jgar.2020.09.029","article-title":"Attainment of therapeutic posaconazole serum levels during co-administration with rifampicin","volume":"23","author":"Power","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2025041611020814900_dkae103-B26","first-page":"7823","article-title":"Toxic optic neuropathy due to voriconazole: possible potentiation by reduction of CYP2C19 activity","volume":"25","author":"Orssaud","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025041611020814900_dkae103-B27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jcpt.13539","article-title":"Detecting drug-drug interactions that increase the incidence of long QT syndrome using a spontaneous reporting system","volume":"47","author":"Matsuo","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2025041611020814900_dkae103-B28","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","article-title":"Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025041611020814900_dkae103-B29","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"van Heeswijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2025041611020814900_dkae103-B30","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-associated qt interval prolongation: pointes of interest","volume":"43","author":"Owens","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025041611020814900_dkae103-B31","author":"Janssen Products, LP"},{"key":"2025041611020814900_dkae103-B32","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/jac\/dkx122","article-title":"Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation","volume":"72","author":"Pettit","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025041611020814900_dkae103-B33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.12659\/AJCR.896946","article-title":"Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: an unusual case report","volume":"17","author":"Panos","year":"2016","journal-title":"Am J Case Rep"},{"key":"2025041611020814900_dkae103-B34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S145545","article-title":"Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy","volume":"12","author":"Jenks","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2025041611020814900_dkae103-B35","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00228-019-02663-8","article-title":"The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of x-oh-praziquantel and not 4-oh-praziquantel","volume":"75","author":"Nleya","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2125.2002.01696.x","article-title":"Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects","volume":"54","author":"Lef\u00e8vre","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bcp.12529","article-title":"Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications","volume":"79","author":"Hoglund","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0009-9236(97)90030-8","article-title":"Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide","volume":"62","author":"Jeppesen","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"2025041611020814900_dkae103-B39","first-page":"121","article-title":"Clarithromycin, interval prolongation and torsades de pointes: the need to study case reports","volume":"1","author":"Vieweg","year":"2013","journal-title":"Ther Adv Infect Dis"},{"key":"2025041611020814900_dkae103-B40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2710.2005.00651.x","article-title":"Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers","volume":"30","author":"Ridtitid","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"2025041611020814900_dkae103-B41","author":"Global Initiative for Asthma"},{"key":"2025041611020814900_dkae103-B42","author":"Global Initiative for Chronic Obstructive Lung Disease"},{"key":"2025041611020814900_dkae103-B43","first-page":"555","article-title":"The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A","volume":"24","author":"Manchee","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"2025041611020814900_dkae103-B44","doi-asserted-by":"crossref","first-page":"e009183","DOI":"10.1136\/bmjopen-2015-009183","article-title":"Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis","volume":"5","author":"Tricco","year":"2015","journal-title":"BMJ Open"},{"key":"2025041611020814900_dkae103-B45","author":"GlaxoSmithKline"},{"key":"2025041611020814900_dkae103-B46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2012.10.007","article-title":"Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression in adults with cystic fibrosis","volume":"12","author":"Gilchrist","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2025041611020814900_dkae103-B47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Lebrun-Vignes","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s002280050720","article-title":"The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone","volume":"56","author":"Varis","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B49","doi-asserted-by":"crossref","first-page":"e12751","DOI":"10.1111\/tid.12751","article-title":"Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4","volume":"19","author":"Groll","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"2025041611020814900_dkae103-B50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025041611020814900_dkae103-B51","doi-asserted-by":"crossref","first-page":"dlab026","DOI":"10.1093\/jacamr\/dlab026","article-title":"A retrospective \u2018real-world\u2019 cohort study of azole therapeutic drug monitoring and evolution of antifungal resistance in cystic fibrosis","volume":"3","author":"Di Paolo","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2025041611020814900_dkae103-B52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1399-3062.2009.00384.x","article-title":"Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients","volume":"11","author":"Berge","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"2025041611020814900_dkae103-B53","doi-asserted-by":"crossref","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025041611020814900_dkae103-B54","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.3390\/jcm11195756","article-title":"Variability of isavuconazole trough concentrations during longitudinal therapeutic drug monitoring","volume":"11","author":"Bolcato","year":"2022","journal-title":"J Clin Med"},{"key":"2025041611020814900_dkae103-B55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/jof9020211","article-title":"Population pharmacokinetics of isavuconazole in critical care patients with covid-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses","volume":"9","author":"Perez","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2025041611020814900_dkae103-B56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2023.01.005","article-title":"Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: focus on Trikafta\u00ae\/Kaftrio\u00ae","volume":"22","author":"Purkayastha","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025041611020814900_dkae103-B57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/17425255.2023.2220960","article-title":"Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications","volume":"19","author":"Hong","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025041611020814900_dkae103-B58","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/antibiotics10111330","article-title":"Clinically relevant interactions with anti-infectives on intensive care units\u2014a multicenter Delphi study","volume":"10","author":"Koeck","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025041611020814900_dkae103-B59","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s12325-019-01115-0","article-title":"Choosing the right antifungal agent in ICU patients","volume":"36","author":"Chatelon","year":"2019","journal-title":"Adv Ther"},{"key":"2025041611020814900_dkae103-B60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/bcp.14994","article-title":"Clinical evaluation of the potential drug-drug interactions of savolitinib: interaction with rifampicin, itraconazole, famotidine or midazolam","volume":"88","author":"Ren","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B61","author":"Pfizer Inc."},{"key":"2025041611020814900_dkae103-B62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-012-1310-x","article-title":"Azole interactions with multidrug therapy in pediatric oncology","volume":"69","author":"Ruggiero","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"2025041611020814900_dkae103-B63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bdd.291","article-title":"Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers","volume":"23","author":"Kang","year":"2002","journal-title":"Biopharm Drug Dispos"},{"issue":"Suppl 1","key":"2025041611020814900_dkae103-B65","first-page":"56","article-title":"Effect of omeprazole on the steady-state pharmacokinetics of voriconazole","volume":"56","author":"Wood","year":"2003","journal-title":"British J Pharmacol"},{"key":"2025041611020814900_dkae103-B66","author":"Food and Drug Administration Center for Drug Evaluation and Research."},{"key":"2025041611020814900_dkae103-B67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s43044-023-00385-y","article-title":"Ondansetron-induced QT prolongation among various age groups: a systematic review and meta-analysis","volume":"75","author":"Singh","year":"2023","journal-title":"Egypt Heart J"},{"key":"2025041611020814900_dkae103-B68","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New perspectives on antimicrobial agents: isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025041611020814900_dkae103-B69","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cpt.620","article-title":"QT interval shortening with isavuconazole: in vitro and in vivo effects on cardiac repolarization","volume":"101","author":"Keirns","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"2025041611020814900_dkae103-B70","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-2005-872510","article-title":"Drug interactions of antimicrobial agents in children with cancer","volume":"217","author":"Langebrake","year":"2005","journal-title":"Klin Padiatr"},{"key":"2025041611020814900_dkae103-B71","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40262-021-00994-3","article-title":"Clinical pharmacokinetics of triazoles in pediatric patients","volume":"60","author":"Bury","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2025041611020814900_dkae103-B72","doi-asserted-by":"crossref","first-page":"2786914","DOI":"10.1155\/2022\/2786914","article-title":"Clinically significant cytochrome p450-mediated drug-drug interactions in children admitted to intensive care units","volume":"2022","author":"Li","year":"2022","journal-title":"Int J Clin Pract"},{"key":"2025041611020814900_dkae103-B73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/1752-1947-5-333","article-title":"Cardiac arrest provoked by itraconazole and amiodarone interaction: a case report","volume":"5","author":"Tsimogianni","year":"2011","journal-title":"J Med Case Rep"},{"key":"2025041611020814900_dkae103-B74","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"key":"2025041611020814900_dkae103-B75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11531850-000000000-00000","article-title":"Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA adverse event reporting system","volume":"33","author":"Poluzzi","year":"2010","journal-title":"Drug Saf"},{"key":"2025041611020814900_dkae103-B76","first-page":"228","article-title":"Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone","volume":"74","author":"Mourad","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025041611020814900_dkae103-B77","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcrc.2012.10.014","article-title":"Drug-drug interactions contributing to QT prolongation in cardiac intensive care units","volume":"28","author":"Armahizer","year":"2013","journal-title":"J Crit Care"},{"key":"2025041611020814900_dkae103-B78","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cpt.1990","article-title":"Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants","volume":"109","author":"Salerno","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025041611020814900_dkae103-B79","author":"Merck Inc"},{"key":"2025041611020814900_dkae103-B80","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.bbmt.2012.04.015","article-title":"Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants","volume":"18","author":"Kubiak","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025041611020814900_dkae103-B81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jac\/dkh022","article-title":"Pharmacokinetic interaction between voriconazole and ciclosporin a following allogeneic bone marrow transplantation","volume":"53","author":"Groll","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2025041611020814900_dkae103-B82","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1078155217701293","article-title":"Clinical impact and management of fluconazole discontinuation on sirolimus levels in bone marrow transplant patients","volume":"24","author":"Nwaroh","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"2025041611020814900_dkae103-B83","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00228-017-2245-z","article-title":"Tolerability of new antiepileptic drugs: a network meta-analysis","volume":"73","author":"Zaccara","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B84","author":"Pfizer, Inc"},{"key":"2025041611020814900_dkae103-B85","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41409-020-0786-8","article-title":"A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD","volume":"55","author":"Hughes","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2025041611020814900_dkae103-B86","doi-asserted-by":"crossref","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin Transplant"},{"key":"2025041611020814900_dkae103-B87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1684\/epd.2021.1261","article-title":"A review of pharmacokinetic drug interactions between antimicrobial and antiseizure medications in children","volume":"23","author":"Zaccara","year":"2021","journal-title":"Epileptic Disord"},{"key":"2025041611020814900_dkae103-B88","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s11096-014-0011-1","article-title":"Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients","volume":"36","author":"Fern\u00e1ndez de Palencia Espinosa","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"2025041611020814900_dkae103-B89","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/jac\/dkr223","article-title":"Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia","volume":"66","author":"van Schie","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2025041611020814900_dkae103-B90","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0090-9556(24)14920-3","article-title":"The effect of fluconazole on cyclophosphamide metabolism in children","volume":"27","author":"Yule","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"2025041611020814900_dkae103-B91","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s002800000220","article-title":"Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion","volume":"47","author":"Yule","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025041611020814900_dkae103-B92","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/jcph.1935","article-title":"Physiologically based pharmacokinetic modeling for selumetinib to evaluate drug-drug interactions and pediatric dose regimens","volume":"61","author":"Cohen-Rabbie","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B93","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2025041611020814900_dkae103-B94","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025041611020814900_dkae103-B95","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"2025041611020814900_dkae103-B96","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-020-04186-0","article-title":"Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia","volume":"99","author":"Meg\u00edas-Vericat","year":"2020","journal-title":"Ann Hematol"},{"key":"2025041611020814900_dkae103-B97","article-title":"Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome","volume-title":"Cancer","author":"Dinh","year":"2024"},{"key":"2025041611020814900_dkae103-B98","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2025041611020814900_dkae103-B99","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/jof8060583","article-title":"High incidence of invasive fungal diseases in patients with FLT3-mutated AML treated with midostaurin: results of a multicenter observational SEIFEM study","volume":"8","author":"Cattaneo","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2025041611020814900_dkae103-B100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.116.072744","article-title":"Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug","volume":"45","author":"He","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"2025041611020814900_dkae103-B101","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"key":"2025041611020814900_dkae103-B102","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/17474086.2020.1752175","article-title":"Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape","volume":"13","author":"Shapiro","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"2025041611020814900_dkae103-B103","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Ann Hematol"},{"key":"2025041611020814900_dkae103-B104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","article-title":"Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)","volume":"90","author":"Sechaud","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025041611020814900_dkae103-B105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40262-016-0453-9","article-title":"Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"56","author":"Freise","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2025041611020814900_dkae103-B106","doi-asserted-by":"crossref","first-page":"E422","DOI":"10.1002\/ajh.26707","article-title":"Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study","volume":"97","author":"Jonas","year":"2022","journal-title":"Am J Hematol"},{"key":"2025041611020814900_dkae103-B107","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1080\/10428194.2018.1460474","article-title":"A drug-drug interaction study of ibrutinib with moderate\/strong CYP3A4 inhibitors in patients with B-cell malignancies","volume":"59","author":"de Jong","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2025041611020814900_dkae103-B108","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2147\/DDDT.S354270","article-title":"Co-administration with voriconazole doubles the exposure of ruxolitinib in patients with hematological malignancies","volume":"16","author":"Zhao","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"2025041611020814900_dkae103-B109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000513989","article-title":"Choosing antifungals for the midostaurin-treated patient: does CYP3A4 outweigh recommendations? A brief insight from real life","volume":"66","author":"Menna","year":"2021","journal-title":"Chemotherapy"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/6\/1203\/58036470\/dkae103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/6\/1203\/58036470\/dkae103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T11:02:44Z","timestamp":1744801364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/6\/1203\/7647009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":109,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae103","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,4,17]]}}}